Tagrisso
A prescription medicine for certain lung cancers with changes in the epidermal growth factor receptor gene.
Imfinzi
An immune-system treatment used for several cancers, including lung, bladder, liver and stomach cancers.
Farxiga/Forxiga
A tablet used for type 2 diabetes, heart failure and chronic kidney disease.
Ultomiris
A long-acting medicine for rare diseases in which the immune system damages blood cells or other tissues.
Fasenra
An injected medicine for severe asthma and certain other conditions involving high levels of eosinophils, a type of white blood cell.
Enhertu
A targeted cancer medicine for cancers with high or altered levels of human epidermal growth factor receptor 2.
AstraZeneca develops, makes and sells prescription medicines. Its medicines treat several types of cancer, heart and kidney conditions, breathing and immune disorders, and rare diseases. It also works with other drug companies to develop and sell some medicines, sharing revenue from those partnerships.
Gebouwd uit de eigen deponeringen van Astrazeneca plc bij de Amerikaanse toezichthouder Securities and Exchange Commission (SEC). De cijfers zijn zoals gerapporteerd, met de historie per aandeel herrekend naar de huidige aandelenbasis. Dit beschrijft een bedrijf — het is geen beleggingsadvies en geen aanbeveling om iets te kopen of te verkopen.
The themes Astrazeneca is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
US$ 184,49+0,1%slot 13 nov
Cijfers tot en met 30 september 2026, uit de 6-K ingediend op 30 oktober 2026
AstraZeneca sells prescription medicines for cancer, heart and kidney disease, lung conditions and rare disorders to patients through healthcare systems worldwide.
Grade B+
De balk onder de koers toont het cijfer op elke datum, alleen gebaseerd op de stukken die toen al openbaar waren.
Toont 2 van 26 kwartalen van de cijferhistorie van Astrazeneca plc. De andere 24 lopen terug tot maart 2018.